Abstract

Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.

Original languageEnglish
Article number100335
JournalJTO Clinical and Research Reports
Volume3
Issue number8
DOIs
StatePublished - Aug 2022
Externally publishedYes

Funding

FundersFunder number
Arrys Therapeutics
CytomX Therapeutics
Daiichi
Ferrer
Gilead Pharmaceuticals
International Association for the Study of Lung Cancer/Lung Ambition Alliance
Jazz
Persan Farma
RTP
Bristol-Myers Squibb Foundation
Israel Cancer Research Fund
AMGEN
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
Genentech
GlaxoSmithKline
Johnson and Johnson
Merck
Novartis
Roche
Sanofi
Boehringer Ingelheim
Takeda Pharmaceutical Company
Janssen Pharmaceuticals
Merck Sharp and Dohme
Les Laboratories Pierre Fabre
ACEA Biosciences
Clovis Oncology
Fresenius KabiEP19305434.3
G1 Therapeutics
Daiichi-Sankyo
Eisai
Angelini Pharma

    Keywords

    • COVID-19
    • Cancer
    • NSCLC
    • Registry
    • TERAVOLT
    • Thoracic

    Fingerprint

    Dive into the research topics of 'Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis'. Together they form a unique fingerprint.

    Cite this